Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease
NCT01176240Phase 3Completed
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Jun 2010
- Primary completion
- Oct 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neurogenic Orthostatic Hypotension (nOH) comparing Droxidopa with Placebo (2 arms). Primary endpoints: Orthostatic Hypotension Questionnaire Score at 8 weeks and Orthostatic Hypotension Symptom Assessment Item 1 at 1 week. Started Jun 2010; status: completed.
02
Drugs
droxidopa
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT01176240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01176240.